Develops and manufactures high-quality plastic films. Specializes in biaxially-oriented polyethylene terephthalate (BOPET) film. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 279% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 279% a year on average.
The company sells $10.2B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $1.9B against $10.2B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.